Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model

Molecular Imaging and Biology

Volumn 14, Issue 5, 2012, Pages 617-624

  Mudd, Sarah R ^a,b   Holich, Kimberley D ^a   Voorbach, Martin J ^a   Cole, Todd B ^a   Reuter, David R ^a   Tapang, Paul ^a   Bukofzer, Gail ^a   Chakravartty, Arunava ^a   Donawho, Cherrie K ^a   Palma, Joann P ^a   Fox, Gerard B ^a   Day, Mark ^a   Luo, Yanping ^a  

^a ABBOTT LABORATORIES   (United States)

^b Dept AP4A 1 ^*  (United States)

Author keywords

FDG; FLT; Irinotecan; PET

Indexed keywords

3' FLUOROTHYMIDINE; CASPASE 3; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; KI 67 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CELL PROLIFERATION; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; TREATMENT RESPONSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS;

EID: 84870449755     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0529-8     Document Type: Article

References (34)

1. Shields AF (2006) Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8(3):141-150
2. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7 (7):591-607
3. Pien HH, Fischman AJ, Thrall JH, Sorensen AG (2005) Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov Today 10(4):259-266
4. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S-80S
5. Shields AF, Grierson JR, Dohmen BM et al (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4(11):1334-1336
6. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43(9):1210-1217
7. Seitz U, Wagner M, Neumaier B et al (2002) Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′- deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 29(9):1174-1181
8. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH (2004) [18 F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31(12):1659-1672
9. Waldherr C, Mellinghoff IK, Tran C et al (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′- deoxy-3′-18 F-fluorothymidine PET. J Nucl Med 46(1):114-120
10. Barthel H, Cleij MC, Collingridge DR et al (2003) 3′-Deoxy- 3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63(13):3791-3798
11. Schiepers C, Dahlbom M, Chen W et al (2010) Kinetics of 3′-deoxy-3′- 18 F-fluorothymidine during treatment monitoring of recurrent highgrade glioma. J Nucl Med 51(5):720-727
12. Dittmann H, Dohmen BM, Kehlbach R et al (2002) Early changes in [18 F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29(11):1462-1469
13. Na YS, Jung KA, Kim SM et al (2010) The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models. Cancer Chemother Pharmacol 68(2):389-398
14. Moroz MA, Kochetkov T, Cai S et al (2011) Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18 F]fluoro-2-deoxyglucose and 3′-deoxy-3′-[18 F]fluorothymidine imaging. Clin Cancer Res 17(5):1099-1110
15. Leyton J, Smith G, Lees M et al (2008) Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 7(9):3112-3121
16. Leyton J, Alao JP, Da Costa M et al (2006) In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy- 3′-[18 F]fluorothymidine positron emission tomography. Cancer Res 66 (15):7621-7629
17. Weekes J, Lam AK, Sebesan S, Ho YH (2009) Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J Gastroenterol 15(29):3597-3602
18. Palma JP, Wang YC, Rodriguez LE et al (2009) ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 15(23):7277-7290
19. Aide N, Poulain L, Briand M et al (2009) Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging 36(3):396-405
20. Sharma RI, Smith TA (2008) Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18 F-FDG incorporation corresponding to hexokinase activity and glucose transport. J Nucl Med 49(8):1386-1394
21. Takeba Y, Sekine S, Kumai T et al (2007) Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull 30(8):1400- 1406
22. Haberkorn U, Bellemann ME, Brix G et al (2001) Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med 28(4):418-425
23. Takei T, Kuge Y, Zhao S et al (2005) Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18 F-FDG, and histologic evaluation. J Nucl Med 46(5):794-799
24. Teicher BA (2008) Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 75(6):1262- 1271
25. Olivieri G, Micheli A (1983) Mitotic delay and repair in human lymphocytes. Mutat Res 122(1):65-72
26. Aguda BD (1999) A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system. Proc Natl Acad Sci U S A 96 (20):11352-11357
27. Furuta M, Hasegawa M, Hayakawa K et al (1997) Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med 24(4):435-438
28. Fishel ML, He Y, Reed AM et al (2008) Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst) 7(2):177-186
29. Chen YL, Eriksson S, Chang ZF (2010) Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem 285(35):27327-27335
30. Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P (1998) Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 42(2):165-170
31. Chen W, Delaloye S, Silverman DH et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18 F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25(30):4714-4721
32. Goshen E, Davidson T, Zwas ST,AderkaD(2006) PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 5(1):37-43
33. El-Deiry WS, Sigman CC, Kelloff GJ (2006) Imaging and oncologic drug development. J Clin Oncol 24(20):3261-3273
34. Kelloff GJ, Hoffman JM, Johnson B et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11(8):2785-2808